Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Kiromic Biopharma, Inc.: Filed Certificate of Amendment to the Certificate of Designation of Series C Convertible Voting Preferred Stock to designate 14,000 shares as Series C Convertible Voting Preferred Stock (effective 2023-07-18).
- Change
- charter amendment
- Effective
- 2023-07-18
Exact text from the filing
On July 18, 2023, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Voting Preferred Stock with the Delaware Secretary of State designating 14,000 shares of its authorized and unissued preferred stock as Series C Convertible Voting Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Kiromic Biopharma, Inc. entered into Exchange Agreement with the holder of promissory notes valued at aggregate principal amount of $6 million (effective 2023-07-18).
- Action
- entry
- Counterparty
- the holder of promissory notes
- Value
- aggregate principal amount of $6 million
- Effective
- 2023-07-18
Exact text from the filing
On July 18, 2023, Kiromic BioPharma, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with the holder of promissory notes of the Company (the “Holder”) pursuant to which the Holder agreed to exchange aggregate principal amount of $6 million of the Company’s 25% Senior Secured Convertible Promissory Notes (the “Exchange Notes”) for 6,000 shares of Series C Convertible Voting Preferred Stock (the “Series C Stock”).
View on SEC.gov